With the ongoing struggle in the launch of its new product, Amgen Inc’s first quarter profits have dropped by 3.6%.

The expectations of the analysts were exceeded by the overall results of the Thousand Oaks, California. This has been achieved as a result of strong sales of the regular drugs manufactured by the firm.

There have been additions in profit due to the contributions made by the sale of the new bone drug for the aid of patients suffering from Cancer. The name of the drug is Xgeva and it is one of the strong reasons for the flourishing profit of the firm.

With the recent changes made in the rules for reimbursement, the third largest drug last year, Epogen has received a huge setback. There was disappointment faced by the osteoporosis drug, Prolia as well due to the same reasons.

There have been a number of pressures faced by Amgen, the drug. Important features for its growth have been bone drugs like Xgreva and Prolia. The pressures these drugs have faced have been a result of the regulatory issues and rising competition.

"This increase is unusual for Amgen, which has been and remains disciplined at having revenues lead expenses”, Amgen Chief Executive Kevin Sharer said in a conference call Wednesday.